ArticleTechnology in cancer research & treatment
A Clinical-Radiomics Nomogram Predicts Early Tumor Necrosis After Transarterial Chemoembolization for Hepatocellular Carcinoma.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionWe introduce a standardized necrosis rate-percent reduction in enhancing tumor diameter normalized by baseline tumor diameter-with a threshold of ≥30%. This endpoint is derived from the mRECIST partial response criteria but is normalized to mitigate tumor size-dependent bias. A clinical-radiomics model was developed to assess necrosis in hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE).MethodsRetrospectively, 95 HCC patients undergoing TACE were included. Radiomics features were selected via LASSO regression, and clinical variables via logistic regression. Separate radiomics and clinical models were developed, and a combined model was constructed using multivariable logistic regression. The cohort was randomly split into training (70%) and validation (30%) sets, with all preprocessing, feature selection, and model training confined to the training set to prevent data leakage. Model performance was evaluated using discrimination (AUC), calibration, clinical utility (decision curve analysis), and a nomogram.ResultsFrom 1,316 extracted radiomics features, six were retained for Rad-score calculation. Key clinical predictors included hepatitis group, standardized viable tumor ratio, and vascular invasion. The integrated model achieved AUCs of 0.865 (95% CI: 0.768-0.961) in training and 0.853 (95% CI: 0.716-0.990) in validation (n=29), outperforming the clinical model (AUCs: 0.808 (95% CI: 0.695-0.922) and 0.666 (95% CI: 0.465-0.866), respectively). Decision curve analysis and calibration plots confirmed the combined model's superior performance.ConclusionThe radiomics-clinical nomogram, based on a standardized necrosis rate, may enable early prediction of TACE response, offering potential insights for therapeutic decision-making, risk stratification, and liver transplantation management. External validation is warranted before clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.